NCT00338754View on ClinicalTrials.gov

Adalimumab in Adult Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

160

Participants

Timeline

Start Date

November 30, 2005

Conditions

Psoriasis

Interventions

DRUG

Human anti-TNF monoclonal antibody adalimumab/ up to 24 weeks

Trial Locations (8)

Unknown

Chugoku

Chūbu

Hokkaido

Kanto

Kinki

Kyusyu

Shikoku

Tōhoku

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Eisai Limited

INDUSTRY

lead

Abbott

INDUSTRY